Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor

Abstract

The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1((phenylsulfanyl)methyl) propyl)amino)-3((trifluoromethyl)sulfonyl)benzenesulfonamide, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer for treating proliferative disorders. The invention is further directed to process for preparing the pharmaceutical dosage form.